EA201491671A1 - Гетероциклильные соединения - Google Patents

Гетероциклильные соединения

Info

Publication number
EA201491671A1
EA201491671A1 EA201491671A EA201491671A EA201491671A1 EA 201491671 A1 EA201491671 A1 EA 201491671A1 EA 201491671 A EA201491671 A EA 201491671A EA 201491671 A EA201491671 A EA 201491671A EA 201491671 A1 EA201491671 A1 EA 201491671A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
heterocyclic compounds
compounds
heteroaryl compounds
tautomers
Prior art date
Application number
EA201491671A
Other languages
English (en)
Other versions
EA029768B1 (ru
Inventor
Бхавеш Даве
Ракеш Кумар Банерджи
Самирон Пхукан
Абхиджит Датта Ходже
Раджкумар Хангарге
Джитендра Самбхаджи Джадхав
Венката П. Палле
Раджендер Кумар Камбодж
Original Assignee
Люпин Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Люпин Лимитед filed Critical Люпин Лимитед
Publication of EA201491671A1 publication Critical patent/EA201491671A1/ru
Publication of EA029768B1 publication Critical patent/EA029768B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к гетероарильным соединениям, таким как ингибиторы MEK. Настоящее изобретение включает гетероарильные соединения с формулой (I), их таутомеры и фармацевтически приемлемые соли, комбинации с подходящим лекарственным препаратом и их фармацевтические композиции. Настоящее изобретение также включает способ получения указанных соединений и предусматривает их применение в терапии.
EA201491671A 2012-03-14 2013-03-11 Гетероциклильные соединения EA029768B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051915 WO2013136254A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds

Publications (2)

Publication Number Publication Date
EA201491671A1 true EA201491671A1 (ru) 2014-12-30
EA029768B1 EA029768B1 (ru) 2018-05-31

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201491672A EA028232B1 (ru) 2012-03-14 2013-03-11 Гетероциклильные соединения как ингибиторы mek
EA201491671A EA029768B1 (ru) 2012-03-14 2013-03-11 Гетероциклильные соединения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201491672A EA028232B1 (ru) 2012-03-14 2013-03-11 Гетероциклильные соединения как ингибиторы mek

Country Status (36)

Country Link
US (5) US9428499B2 (ru)
EP (2) EP2834237B1 (ru)
JP (3) JP6431770B2 (ru)
KR (4) KR20140138910A (ru)
CN (4) CN104271577A (ru)
AP (2) AP3859A (ru)
AU (4) AU2013234014B2 (ru)
BR (1) BR112014022713B1 (ru)
CA (2) CA2865167C (ru)
CL (2) CL2014002412A1 (ru)
CO (2) CO7170131A2 (ru)
CR (2) CR20140464A (ru)
CU (2) CU24272B1 (ru)
DK (2) DK2834236T3 (ru)
DO (2) DOP2014000204A (ru)
EA (2) EA028232B1 (ru)
ES (2) ES2741896T3 (ru)
GE (2) GEP201706671B (ru)
GT (2) GT201400196A (ru)
HK (2) HK1202538A1 (ru)
IL (2) IL234559A (ru)
IN (2) IN2014MN01755A (ru)
MA (2) MA37400B1 (ru)
MX (3) MX355526B (ru)
MY (2) MY174188A (ru)
NI (2) NI201400108A (ru)
NZ (2) NZ629432A (ru)
PE (2) PE20141973A1 (ru)
PH (2) PH12014502041B1 (ru)
PL (1) PL2834237T3 (ru)
SG (2) SG11201405006PA (ru)
TN (2) TN2014000356A1 (ru)
TR (1) TR201811976T4 (ru)
UA (2) UA114907C2 (ru)
WO (2) WO2013136254A1 (ru)
ZA (1) ZA201406186B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
KR20140138910A (ko) 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
CN104936945B (zh) * 2013-10-25 2017-11-03 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
LT3728254T (lt) 2017-12-21 2023-05-10 Boehringer Ingelheim International Gmbh Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114375202A (zh) 2019-06-19 2022-04-19 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021018866A1 (en) * 2019-07-30 2021-02-04 Edvince Ab Mek inhibitor for treatment of stroke
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116034106A (zh) 2020-06-02 2023-04-28 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
AU2022258968A1 (en) * 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
BRPI0511967B8 (pt) * 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
EA201101533A1 (ru) 2009-04-21 2012-05-30 Новартис Аг Гетероциклические соединения в качестве ингибиторов mek
KR20140138910A (ko) 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물

Also Published As

Publication number Publication date
US9827247B2 (en) 2017-11-28
CL2014002411A1 (es) 2015-04-06
WO2013136249A1 (en) 2013-09-19
PH12014502040A1 (en) 2014-11-24
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
CR20140464A (es) 2014-11-28
GEP201706774B (en) 2017-11-27
AU2018202568B2 (en) 2019-05-09
DOP2014000203A (es) 2015-02-15
SG11201405007QA (en) 2014-10-30
EP2834236B1 (en) 2019-05-22
KR20140138911A (ko) 2014-12-04
MX2014010925A (es) 2015-04-10
US20160331753A1 (en) 2016-11-17
KR20190073597A (ko) 2019-06-26
MY174188A (en) 2020-03-12
CN104271577A (zh) 2015-01-07
UA114906C2 (uk) 2017-08-28
US9555035B2 (en) 2017-01-31
BR112014022713B1 (pt) 2021-09-08
PH12014502041A1 (en) 2014-11-24
US9969731B2 (en) 2018-05-15
KR102240101B1 (ko) 2021-04-14
ZA201406186B (en) 2016-06-29
ES2684517T3 (es) 2018-10-03
AU2013234009B2 (en) 2016-10-27
DK2834236T3 (da) 2019-08-26
US9573944B2 (en) 2017-02-21
US9428499B2 (en) 2016-08-30
CA2865164C (en) 2021-06-08
MX366426B (es) 2019-07-08
CU20140109A7 (es) 2014-11-27
DK2834237T3 (en) 2018-08-27
PE20141974A1 (es) 2014-12-12
SG11201405006PA (en) 2014-10-30
US20170101408A1 (en) 2017-04-13
IN2014MN01754A (ru) 2015-07-03
US20150133424A1 (en) 2015-05-14
IN2014MN01755A (ru) 2015-07-03
AU2017200493B2 (en) 2018-03-29
AU2013234014A1 (en) 2014-09-25
IL234560A (en) 2017-06-29
NZ629432A (en) 2017-01-27
CO7170131A2 (es) 2015-01-28
HK1206020A1 (en) 2015-12-31
MA37400B1 (fr) 2019-11-29
MX355474B (es) 2018-04-16
CL2014002412A1 (es) 2015-03-06
AP3859A (en) 2016-10-31
JP2015509975A (ja) 2015-04-02
ES2741896T3 (es) 2020-02-12
NI201400108A (es) 2014-11-28
JP6093384B2 (ja) 2017-03-08
CA2865164A1 (en) 2013-09-19
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
PH12014502041B1 (en) 2014-11-24
CN104203947A (zh) 2014-12-10
NI201400107A (es) 2014-11-26
GT201400195A (es) 2017-11-09
EP2834236A1 (en) 2015-02-11
EP2834237A1 (en) 2015-02-11
AP2014008008A0 (en) 2014-10-31
US20170112840A1 (en) 2017-04-27
UA114907C2 (uk) 2017-08-28
CU24272B1 (es) 2017-08-08
AP2014008009A0 (en) 2014-10-31
AU2013234014B2 (en) 2017-02-02
CU20140110A7 (es) 2014-11-27
GT201400196A (es) 2017-09-28
CU24335B1 (es) 2018-04-03
MA37405A1 (fr) 2016-03-31
BR112014022713A2 (ru) 2017-06-20
MA37400A1 (fr) 2016-05-31
CA2865167C (en) 2019-08-06
CN107698585A (zh) 2018-02-16
TN2014000357A1 (en) 2015-12-21
JP2015514056A (ja) 2015-05-18
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
CN108383836B (zh) 2021-11-12
MX355526B (es) 2018-04-20
KR20190100472A (ko) 2019-08-28
PH12014502040B1 (en) 2014-11-24
KR102241111B1 (ko) 2021-04-15
KR20140138910A (ko) 2014-12-04
US20150299186A1 (en) 2015-10-22
CA2865167A1 (en) 2013-09-19
CN108383836A (zh) 2018-08-10
IL234559A (en) 2017-06-29
MX2014010928A (es) 2015-04-10
JP6431770B2 (ja) 2018-11-28
AU2017200493A1 (en) 2017-02-16
GEP201706671B (en) 2017-05-25
AP3834A (en) 2016-09-30
EA028232B1 (ru) 2017-10-31
DOP2014000204A (es) 2015-02-15
AU2018202568A1 (en) 2018-05-10
EA029768B1 (ru) 2018-05-31
WO2013136254A1 (en) 2013-09-19
PE20141973A1 (es) 2014-12-12
JP6630771B2 (ja) 2020-01-15
TR201811976T4 (tr) 2018-09-21
JP2018115215A (ja) 2018-07-26
EP2834237B1 (en) 2018-06-06
AU2013234009A1 (en) 2014-09-25
NZ629442A (en) 2016-12-23
PL2834237T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
EA201491671A1 (ru) Гетероциклильные соединения
PH12020550552A1 (en) Inhibitors of hepatitis c virus
EA201591195A1 (ru) Новые хинолоновые производные
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
IN2015DN01119A (ru)
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201690888A1 (ru) Новые гетероциклические соединения
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201391820A1 (ru) Гетероциклические сульфонамидные производные
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao